Angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
=== Education === Yonath was accepted to Tichon Hadash high school since her mother could not pay the tuition, she traded her time teaching math lessons to students, which helped pay for her schooling. At a young age, she said, she was inspired by the scientist Marie Curie. However, she stressed that Curie, whom she as a child was fascinated by after reading her biography, was not her "role model". She returned to Jerusalem for college, graduating from the Hebrew University of Jerusalem with a bachelor's degree in chemistry in 1962, and a master's degree in biochemistry in 1964. In 1968, she obtained her PhD from the Weizmann Institute of Science for X-ray crystallographic studies on the structure of collagen, with Wolfie Traub as her PhD advisor.
=== Trademark lawsuit against Nike === In July 2026, 7-Eleven filed a trademark infringement lawsuit against Nike, Inc. in the United States District Court for the Northern District of Texas, seeking to block the release of a new Nike Air Max 95 "Big Bubble" sneaker. The complaint alleged that the shoe's colorway imitated, in a "confusingly similar" manner, the orange, green, and red color combination of the 7-Eleven logo, which the company has used commercially since the 1980s and for which it holds multiple federal trademark registrations. 7-Eleven argued that the design could mislead consumers into believing that Nike had a partnership or collaboration with the company, noting that some product listings and media outlets had referred to the sneaker as the "7-Eleven" shoe or described it as "7-Eleven-inspired". The complaint also pointed to the shoe's planned release date of July 11, which coincides with the company's annual "7-Eleven Day" promotion, as evidence of deliberate association. 7-Eleven asked the court for a permanent injunction barring the sale and promotion of the shoe, a recall and destruction of existing inventory, disgorgement of profits, and damages. According to federal court records, Nike was served with the complaint on July 6, 2026; a hearing date had not yet been scheduled.
The Soviet Union repressed homosexuality. Even during the period when homosexuality was officially legal after the abolition of the Tsarist penal code criminalizing it, Soviet courts attempted to repress non-traditional forms of sexuality, which were widely viewed by Russian revolutionaries as a form of capitalist decadence despite more liberal views on homosexuality from Soviet academic sexologists. After Stalin's consolidation of power, homosexuality became officially recriminalised in 1934. The increased homophobia during this time interval was driven by the economic demands of the First Five-Year Plan, as well as the NKVD's view of homosexuals as "socially harmful elements", although even during this heightened period of repression, a clandestine homosexual subculture was able to persist. Homosexuality remained a criminal offence throughout the remainder of the Soviet Union's existence.
== Affiliated hospitals == Rajindra Hospital, Patiala with 1009 beds was attached to the college in early 1951. The hospital was equipped with all the latest apparatus and instruments to make it fit for imparting clinical teaching to the students. Two well designed, spacious and well lighted lecture theatres equipped with arrangements for epidiascopes projections and audio visual aids were provided on the hospital side in addition to four lecture theatres of similar design on college side for basic departments. The department of Tuberculosis and Respiratory Medicine/Pulmonary Medicine is located in a separate campus, known as the Tuberculosis Centre, Patiala which started functioning on 25 July 1953 with 22 observation beds, 11 for male and 11 for female patients with Tuberculosis. It is popularly known as TB Hospital or Padma Shri Dr. Khushdeva Singh Chest Diseases Hospital, and currently has a capacity of 121 beds. Primary health centres at Bhadson, Kauli and Tripuri are attached with this college for teaching purposes. There are three hostels, two for girls and one for boys. In addition to this there is one hostel in the Rajindra Hospital also for Doctors/Interns/House surgeons. The college has a very spacious auditorium, big play ground and an open-air theatre. The college is governed by Director Research and Medical Education, Punjab and is affiliated to Baba Farid University of Health Sciences, Faridkot.
Sources: en.wikipedia.org
The therapeutic dosage varies according to the patient's age or clinical condition, but for all treatments with sertraline, it is recommended to start with lower dosages (25 to 50 mg/daily) and adjust according to the patient's therapeutic response, with a maximum maintenance dose of up to 200 mg per day.
A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (a.k.a. shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. Shingles provokes a painful rash with blisters and can be followed by chronic pain (postherpetic neuralgia) and other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination. Two zoster vaccines have been approved for use in people over 50 years old. Shingrix (GSK) is a recombinant subunit vaccine that has been used in many countries since 2017. Zostavax (Merck), in use since 2006, is an attenuated vaccine which consists of a larger-than-normal dose of varicella vaccine. Unlike Shingrix, Zostavax is not suitable for people with immunosuppression or diseases that affect the immune system. Zostavax was discontinued in the United States in November 2020. Shingrix appears to prevent more cases of shingles than Zostavax, although side effects seem to be more frequent. Varicella vaccine is used to prevent diseases caused by the same virus.
5-HTP robustly produces the head-twitch response (HTR) in rodents when administered at relatively high doses. It dose-dependently induces the HTR in mice across a dose range of 50 to 250 mg/kg via intraperitoneal administration, with an inverted U-shaped dose–response curve and maximal induction of the HTR at a dose of 200 mg/kg. Similarly to the case of 5-HTP, intracerebroventricular injection of serotonin, but not peripheral administration of serotonin, produces the HTR. The HTR is induced by serotonergic psychedelics like lysergic acid diethylamide (LSD) and psilocybin and is a behavioral proxy of psychedelic effects. The HTR of 5-HTP is blocked by serotonin 5-HT2A receptor antagonists, which block the hallucinogenic effects of serotonergic psychedelics in humans, is prevented by aromatic L-amino acid decarboxylase (AAAD) inhibitors, which block conversion of 5-HTP into serotonin, and is potentiated by monoamine oxidase A (MAO-A) inhibitors, which prevent the degradation of serotonin and other endogenous tryptamines. It is also suppressed by the serotonin 5-HT1A receptor full agonist 8-OH-DPAT, is greatly augmented by the serotonin 5-HT2C receptor antagonist RS-102221, and is reduced by the trace amine-associated receptor 1 (TAAR1) antagonist EPPTB.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.